Brazilian Guidelines for the Treatment of Outpatients with Suspected or Confirmed COVID-19. A Joint Guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology And...

Background: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil.

Methods: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method.

Results: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation.

Conclusion: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments.

Citing Articles

Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study.

Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F Front Pharmacol. 2024; 15:1402032.

PMID: 39434905 PMC: 11491754. DOI: 10.3389/fphar.2024.1402032.

Antibiotic prescribing guideline recommendations in COVID-19: a systematic survey.

Langford B, Leung V, Lo J, Akl E, Nieuwlaat R, Lotfi T EClinicalMedicine. 2023; 65:102257.

PMID: 37842549 PMC: 10568086. DOI: 10.1016/j.eclinm.2023.102257.

Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API).

Barbosa A, Chebabo A, Starling C, Perez C, Cunha C, de Luna D Ann Clin Microbiol Antimicrob. 2023; 22(1):67.

PMID: 37550690 PMC: 10408214. DOI: 10.1186/s12941-023-00623-w.

COVID-19 mortality in Brazil, 2020-21: consequences of the pandemic inadequate management.

Szwarcwald C, Boccolini C, Almeida W, Soares Filho A, Malta D Arch Public Health. 2022; 80(1):255.

PMID: 36536434 PMC: 9762984. DOI: 10.1186/s13690-022-01012-z.

References

Schunemann H, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R . Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2013; 186(3):E123-42. PMC: 3928232. DOI: 10.1503/cmaj.131237. View

Bhimraj A, Morgan R, Shumaker A, Lavergne V, Baden L, Cheng V . Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020; . PMC: 7197612. DOI: 10.1093/cid/ciaa478. View

Jayk Bernal A, Gomes da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Delos Reyes V . Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021; 386(6):509-520. PMC: 8693688. DOI: 10.1056/NEJMoa2116044. View

Lotfi T, Stevens A, Akl E, Falavigna M, Kredo T, Mathew J . Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines. J Clin Epidemiol. 2021; 135:182-186. PMC: 8022513. DOI: 10.1016/j.jclinepi.2021.03.034. View

Kalil A . Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020; 323(19):1897-1898. DOI: 10.1001/jama.2020.4742. View

Marconi V, Ramanan A, de Bono S, Kartman C, Krishnan V, Liao R . Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9(12):1407-1418. PMC: 8409066. DOI: 10.1016/S2213-2600(21)00331-3. View

Akl E, Morgan R, Rooney A, Beverly B, Katikireddi S, Agarwal A . Developing trustworthy recommendations as part of an urgent response (1-2 weeks): a GRADE concept paper. J Clin Epidemiol. 2020; 129:1-11. PMC: 7526592. DOI: 10.1016/j.jclinepi.2020.09.037. View

Berwanger O . Fluvoxamine for outpatients with COVID-19: where do we stand?. Lancet Glob Health. 2021; 10(1):e2-e3. PMC: 8550914. DOI: 10.1016/S2214-109X(21)00501-5. View

Guimaraes P, Quirk D, Furtado R, Maia L, Saraiva J, Antunes M . Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021; 385(5):406-415. PMC: 8220898. DOI: 10.1056/NEJMoa2101643. View

10.

Azoulay E, De Waele J, Ferrer R, Staudinger T, Borkowska M, Povoa P . International variation in the management of severe COVID-19 patients. Crit Care. 2020; 24(1):486. PMC: 7403819. DOI: 10.1186/s13054-020-03194-w. View

11.

Klimek L, Buhl R, Deitmer T, Plontke S, Wehrmann W, Merk H . Recommendations for use of topical inhalant budesonide in COVID-19 : A Position Paper of the German Society for Applied Allergology (AeDA) and the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO). HNO. 2021; 69(Suppl 2):35-38. PMC: 8284416. DOI: 10.1007/s00106-021-01070-9. View

12.

Falavigna M, Colpani V, Stein C, Azevedo L, Maria Bagattini A, Brito G . Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev Bras Ter Intensiva. 2020; 32(2):166-196. PMC: 7405746. DOI: 10.5935/0103-507x.20200039. View

13.

Schunemann H, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa R, Manja V . GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2016; 81:101-110. DOI: 10.1016/j.jclinepi.2016.09.009. View

14.

Chalmers J, Crichton M, Goeminne P, Cao B, Humbert M, Shteinberg M . Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021; 57(4). PMC: 7947358. DOI: 10.1183/13993003.00048-2021. View

15.

Reis G, Dos Santos Moreira-Silva E, Carla Medeiros Silva D, Thabane L, Cruz Milagres A, Santiago Ferreira T . Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021; 10(1):e42-e51. PMC: 8550952. DOI: 10.1016/S2214-109X(21)00448-4. View

16.

Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4):383-94. DOI: 10.1016/j.jclinepi.2010.04.026. View